Scholarlink

Introduction <p>Pulmonary complications are a major cause of poor outcomes in people living with HIV, yet data on the etiology and mortality predictors remain limited, particularly in middle-income countries.</p> Methods <p>In this retrospective cohort study, we reviewed the clinical records of 117 adults living with HIV (PLWH) with documented pulmonary involvement followed at a tertiary care center in Turkey between 2000 and 2024. Baseline immunovirological status was assessed using CD4 + T lymphocyte counts and plasma HIV-1 RNA levels. Clinical, laboratory, radiological, and microbiological data were collected, and predictors of mortality and length of hospital stay were analyzed.</p> Results <p>A total of 117 PLWH were included; the cohort was predominantly male (91.5%), with a mean age of 44.0 ± 13.7 years, and 45.3% were receiving antiretroviral therapy at presentation. Infectious etiologies, particularly pneumonia (94.9%), predominated. Microbiological confirmation was obtained in 26 patients (22.2%); across the cohort, a total of 39 pathogens were identified (33.3% when counted by pathogen episode), with SARS-CoV-2 (12.8%) and Mycobacterium tuberculosis complex (6.0%) being the most common. Non-infectious pulmonary conditions (such as lung cancer, COPD, asthma, and interstitial lung disease) were observed only in a small minority of patients and, owing to their low numbers, were described descriptively but not analyzed in separate outcome subgroups. The overall mortality rate was 24.8% (29/117). The factors significantly associated with mortality included a low CD4 count (160.4 vs. 288.1 cells/mm³; <i>p</i> = 0.014), low albumin level (2.64 vs. 3.13&#xa0;g/dL; <i>p</i> = 0.003), the need for intubation (OR 70.69, 95% CI 8.63–578.79; <i>p</i> &lt; 0.001), and intensive care unit (ICU) admission (OR 10.71, 95% CI 3.83–29.98; <i>p</i> &lt; 0.001). Pneumococcal vaccination was associated with a reduced mortality risk (OR = 0.20, 95% CI 0.06–0.72; <i>p</i> = 0.008). Higher procalcitonin (β 0.27, 95% CI 0.04–0.51; <i>p</i> = 0.021) and lower albumin levels (β − 4.90, 95% CI − 9.43 to − 0.37; <i>p</i> = 0.034) independently predicted longer hospital stays.</p> Conclusions <p>Pulmonary involvement in HIV remains a serious clinical issue in our setting and was driven predominantly by infectious pneumonias, whereas non-infectious pulmonary conditions were less frequent and could not be evaluated in detail. Early identification of high-risk patients and increased access to preventive strategies, particularly vaccination, are crucial to improving in-hospital outcomes.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pulmonary complications in people living with HIV: a retrospective evaluation of the etiological spectrum and mortality-associated factors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Damla Ertürk,
  • Aslıhan Candevir,
  • Ayşe Akkaya,
  • Süheyla Kömür,
  • Onur Acar,
  • Ferit Kuşçu,
  • Ayşe Seza İnal,
  • Behice Kurtaran,
  • Yeşim Taşova

摘要

Introduction

Pulmonary complications are a major cause of poor outcomes in people living with HIV, yet data on the etiology and mortality predictors remain limited, particularly in middle-income countries.

Methods

In this retrospective cohort study, we reviewed the clinical records of 117 adults living with HIV (PLWH) with documented pulmonary involvement followed at a tertiary care center in Turkey between 2000 and 2024. Baseline immunovirological status was assessed using CD4 + T lymphocyte counts and plasma HIV-1 RNA levels. Clinical, laboratory, radiological, and microbiological data were collected, and predictors of mortality and length of hospital stay were analyzed.

Results

A total of 117 PLWH were included; the cohort was predominantly male (91.5%), with a mean age of 44.0 ± 13.7 years, and 45.3% were receiving antiretroviral therapy at presentation. Infectious etiologies, particularly pneumonia (94.9%), predominated. Microbiological confirmation was obtained in 26 patients (22.2%); across the cohort, a total of 39 pathogens were identified (33.3% when counted by pathogen episode), with SARS-CoV-2 (12.8%) and Mycobacterium tuberculosis complex (6.0%) being the most common. Non-infectious pulmonary conditions (such as lung cancer, COPD, asthma, and interstitial lung disease) were observed only in a small minority of patients and, owing to their low numbers, were described descriptively but not analyzed in separate outcome subgroups. The overall mortality rate was 24.8% (29/117). The factors significantly associated with mortality included a low CD4 count (160.4 vs. 288.1 cells/mm³; p = 0.014), low albumin level (2.64 vs. 3.13 g/dL; p = 0.003), the need for intubation (OR 70.69, 95% CI 8.63–578.79; p < 0.001), and intensive care unit (ICU) admission (OR 10.71, 95% CI 3.83–29.98; p < 0.001). Pneumococcal vaccination was associated with a reduced mortality risk (OR = 0.20, 95% CI 0.06–0.72; p = 0.008). Higher procalcitonin (β 0.27, 95% CI 0.04–0.51; p = 0.021) and lower albumin levels (β − 4.90, 95% CI − 9.43 to − 0.37; p = 0.034) independently predicted longer hospital stays.

Conclusions

Pulmonary involvement in HIV remains a serious clinical issue in our setting and was driven predominantly by infectious pneumonias, whereas non-infectious pulmonary conditions were less frequent and could not be evaluated in detail. Early identification of high-risk patients and increased access to preventive strategies, particularly vaccination, are crucial to improving in-hospital outcomes.

Clinical trial number

Not applicable.